The United States of America, as Represented by the Secretary, Department of Health and Human Services

The Ohio State University

Fudan University

Zhao-you Tang

Carlo M Croce

Xin Wei Wang

Junfang Ji

Hui-chuan Sun

Anuradha Budhu

Anuradha Budha

It is disclosed herein that expression of microRNA-26 is decreased in hepatocellular (HCC) tumor tissue relative to non-cancerous tissue, and that a low level of microRNA-26 is associated with a poor clinical outcome. It is also disclosed herein that a low expression level of microRNA-26 is correlated with a favorable response to interferon (IFN)-&#x3b1; therapy in HCC patients. Thus, provided herein is a method of predicting the clinical outcome of a patient diagnosed with HCC comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. Also provided is a method of selecting a patient diagnosed with HCC as a candidate for IFN-&#x3b1; therapy, comprising detecting the level of microRNA-26 expression in a sample obtained from the patient. A method of identifying therapeutic agents for the treatment of HCC, comprising screening candidate agents in vitro to select an agent that increases expression of microRNA-26 in HCC cells are also provided. Further provided are methods of treating a patient diagnosed with HCC and expressing a low level of miR-26, wherein treatment comprises IFN-&#x3b1; therapy.

Use of MiR-26 family as a predictive marker for hepatocellular carcinoma and responsiveness to therapy

Provided herein are methods and compositions for the diagnosis, prognosis and treatment of Hepatocellular carcinoma (HCC). Also provided are methods of identifying anti-HCC agents.

MicroRNA expression signature for predicting survival and metastases in hepatocellular carcinoma

Growing community of inventors

Shanghai, China

Zhao-you Tang